FDA Approves Sandoz' High-Concentration Version of Adalimumab Biosimilar, Hyrimoz

Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab).

Related Keywords

United States ,America ,Amgen Amjevita ,Keren Haruvi ,Samsung Bioepis ,Sandoz Inc ,North America ,Celltrion Healthcare ,